0.86 (-%)
As of Dec 03, 2024
Source:
We are a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. We are focused on developing (i) a topical formulation for treating side effects from drugs used for the treatment of cancer; (ii) a treatment for mast-cell derived cancers and anaphylaxis; and (iii) a treatment and/or prevention for Alzheimers or other neuroinflammatory diseases. We also have preclinical assets being developed for (i) atopic dermatitis (also known as eczema); (ii) a treatment for asthma and allergies using inhalational administration; (iii) a treatment for lung diseases resulting from bacterial infections; and (iv) a treatment for inflammatory bowel diseases. We are also developing a diagnostic device via a mobile device.
Country | United States |
Headquarters | new york, new york |
Phone Number | 551-578-2261 |
Industry | manufacturing |
CEO | Robb Knie |
Website | www.hoththerapeutics.com |